Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0002023658-25-000098
Filing Date
2025-08-12
Accepted
2025-08-12 16:02:30
Documents
63
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q bcax-20250630.htm   iXBRL 10-Q 1884896
2 EX-10.1 exhibit101sublease_6225.htm EX-10.1 88408
3 EX-10.2 exhibit102-116huntingtonxb.htm EX-10.2 48018
4 EX-31.1 exhibit311q2-25.htm EX-31.1 10498
5 EX-31.2 exhibit312q2-25.htm EX-31.2 10424
6 EX-32.1 exhibit321q2-25.htm EX-32.1 7605
  Complete submission text file 0002023658-25-000098.txt   6007259

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcax-20250630.xsd EX-101.SCH 32412
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bcax-20250630_cal.xml EX-101.CAL 36784
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bcax-20250630_def.xml EX-101.DEF 180210
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcax-20250630_lab.xml EX-101.LAB 471330
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcax-20250630_pre.xml EX-101.PRE 328869
66 EXTRACTED XBRL INSTANCE DOCUMENT bcax-20250630_htm.xml XML 526797
Mailing Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116
Business Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116 617-468-4219
Bicara Therapeutics Inc. (Filer) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42271 | Film No.: 251206515
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)